Hannah Britz

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

Nina Hanke, Sebastian Frechen, Daniel Moj et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 158 citations · Full text

Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens

Daniel Moj, Nina Hanke, Hannah Britz et al. · The AAPS Journal · 2016 · 42 citations

Drug Interactions, Therapeutic Drug Monitoring, Pharmacokinetic Modeling +9

Physiologically‐Based Pharmacokinetic Models for <scp>CYP</scp>1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam

Hannah Britz, Nina Hanke, Anke‐Katrin Volz et al. · CPT Pharmacometrics & Systems Pharmacology · 2019 · 37 citations · Full text

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

Hannah Britz, Nina Hanke, Mitchell E. Taub et al. · Pharmaceutical Research · 2020 · 30 citations · Full text

A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification

Daniel Moj, Hannah Britz, Jürgen Burhenne et al. · Cancer Chemotherapy and Pharmacology · 2017 · 26 citations · Full text

Dose Specification, Pharmacokinetic Modeling, Physiologically-based Pharmacokinetic Modeling +7